Emergent BioSolutions director gets RSUs, stock options

Emergent BioSolutions Inc. director John D. Fowler Jr. received equity compensation for Board and Committee service.

Rhea-AI Filing Summary

Emergent BioSolutions Inc. director John D. Fowler Jr. received equity compensation for Board and Committee service. He was granted 25,344 restricted stock units (RSUs), each representing one share of common stock that will vest on the day prior to the one-year anniversary of the grant date, as long as he remains on the board through that date. He was also granted 11,296 stock options to buy common shares at an exercise price of $7.99 per share, expiring on April 30, 2033, which vest on the same one-year schedule. Following the RSU grant, his direct common stock holdings increased to 30,350 shares.

Insider Trade Summary

Grant/Award: 36,640 shares

Grant/Award 2 txns

Insider FOWLER JOHN D JR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	11,296	$0.00	$0.00
Grant/Award	Common Stock	25,344	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 11,296 contracts (Direct); Common Stock — 30,350 shares (Direct)

Footnotes (3)

1. F1. Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
2. F2. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
3. F3. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

Key Figures

RSUs granted: 25,344 RSUs Options granted: 11,296 options Option exercise price: $7.99 per share +3 more

6 metrics

RSUs granted 25,344 RSUs Annual equity grant for Board and Committee service on April 30, 2026

Options granted 11,296 options Stock options granted for Board and Committee service on April 30, 2026

Option exercise price $7.99 per share Exercise price for 11,296 stock options granted

Option expiration April 30, 2033 Expiration date of granted stock options

Shares held after grant 30,350 shares Director’s direct common stock holdings following RSU grant

Vesting period 1 year from grant RSUs and options vest day prior to one-year anniversary of grant date

Key Terms

restricted stock units ("RSUs"), Stock Incentive Plan, Black-Scholes value, Annual Grant Vesting Date, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Incentive Plan financial

"granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service"

A stock incentive plan is a company program that gives employees or directors pieces of ownership or the right to buy shares over time, similar to receiving a bonus paid in company stock instead of cash. Investors pay attention because these plans align staff incentives with long‑term company performance but can also dilute existing shareholders and affect reported profits when grants are expensed, so they influence both ownership percentages and financial results.

Black-Scholes value financial

"dividing by the Black-Scholes value of a single option calculated as of the date of the grant"

Annual Grant Vesting Date financial

"will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date")"

stock options financial

"Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Emergent BioSolutions (EBS) director John D. Fowler Jr. receive in this Form 4?

Director John D. Fowler Jr. received equity compensation, including 25,344 restricted stock units and 11,296 stock options. These awards were granted for Board and Committee service under Emergent BioSolutions’ stock incentive plan, instead of being open-market share purchases.

How many Emergent BioSolutions (EBS) RSUs were granted to the director and when do they vest?

He was granted 25,344 restricted stock units. Each RSU converts into one share of common stock. The RSUs vest on the day before the one-year anniversary of the April 30, 2026 grant date, assuming he remains a member of the board through that vesting date.

What stock options did John D. Fowler Jr. receive from Emergent BioSolutions (EBS)?

He received 11,296 stock options, each allowing the purchase of one share of common stock at an exercise price of $7.99. These options vest on the same one-year schedule and expire on April 30, 2033, if not exercised earlier.

How did this equity grant change the director’s Emergent BioSolutions (EBS) share holdings?

After the RSU grant, his directly held common stock position increased to 30,350 shares. This figure reflects his ownership immediately following the reported acquisition event, giving a snapshot of his post-grant direct equity stake in the company.

How was the number of Emergent BioSolutions (EBS) stock options granted to the director determined?

The number of options was calculated by taking 25% of the total non-employee director compensation value and dividing it by the Black-Scholes value of a single option. That formula produced the 11,296 options reported in the Form 4 footnotes.

Are the Emergent BioSolutions (EBS) equity awards to the director tied to continued board service?

Yes. Both the RSUs and stock options vest on the day before the one-year anniversary of the grant date, only if John D. Fowler Jr. continues serving on Emergent BioSolutions’ board of directors through that Annual Grant Vesting Date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 05:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FOWLER JOHN D JR

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MARYLAND 20879

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/30/2026		A		25,344(1)	A	$0	30,350	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.99	04/30/2026		A		11,296		(2)	04/30/2033	Common Stock	11,296(3)	$0	11,296	D

Explanation of Responses:

1. Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

2. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

3. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)